Patent ID: 8835501

Claim:
A pharmaceutical composition consisting essentially of: (a) a histone deacetylase (HDAC) inhibitor; and, (b) at least one basic in situ salt former, wherein the salt former is free arginine, meglumine or free meglumine, and, (c) a pharmaceutically acceptable excipient or carrier; wherein said HDAC inhibitor is selected from compounds of the following formula and pharmaceutically acceptable salts thereof: wherein: A is a substituted or unsubstituted: C 6-20 carboaryl, or C 5-20 heteroaryl; Q 1 is: a covalent bond, or a substituted or unsubstituted C 1-7 alkylene, C 2-7 alkenylene; J is: —NR N —S(═O) 2 —, or —S(═O) 2 —NR N —; R N is: —H, or a substituted or unsubstituted C 1-7 alkyl, C 3-20 heterocyclyl, C 6-20 carboaryl, C 5-20 heteroaryl, C 6-20 carboaryl-C 1-7 alkyl, or C 5-20 heteroaryl-C 1-7 alkyl; Q 2 is a substituted or unsubstituted: C 6-20 carboarylene, C 5-20 heteroarylene, C 6-20 carboarylene-C 1-7 alkylene, C 5-20 heteroarylene-C 1-7 alkylene, C 6-20 carboarylene-C 2-7 alkenylene, C 5-20 heteroarylene-C 2-7 alkenylene, C 1-7 alkylene-C 6-20 carboarylene, C 1-7 alkylene-C 5-20 heteroarylene, C 2-7 alkenylene-C 6-20 carboarylene, C 2-7 alkenylene-C 5-20 heteroarylene, C 1-7 alkylene-C 6-20 carboarylene-C 1-7 alkylene, C 1-7 alkylene-C 5-20 heteroarylene-C 1-7 alkylene, C 2-7 alkenylene-C 6-20 carboarylene-C 1-7 alkylene, C 2-7 alkenylene-C 5-20 heteroarylene-C 1-7 alkylene, C 1-7 alkylene-C 6-20 carboarylene-C 2-7 alkenylene, C 1-7 alkylene-C 5-20 heteroarylene-C 2-7 alkenylene, C 2-7 alkenylene-C 6-20 carboarylene-C 2-7 alkenylene, or C 2-7 alkenylene-C 5-20 heteroarylene-C 2-7 alkenylene, and is unsubstituted or substituted.